AZD 2281 (Olaparib, KU-0059436) is a novel, potent orally active PARP (poly ADP-ribose polymerase) inhibitorwith IC50 of 5 and 1 nM for PARP-1and PARP-2 respectively. AZD 2281 (Olaparib, KU-0059436) acts as an inhibitor of the enzyme Poly ADP ribose polymerase (PARP) and is one of the first PARP inhibitors.It induces cancer specific synthetic lethality in homologous recombination repair defective cells, including BRCA-deficient tumors.
Int J Biol Sci. 2018 Oct 3;14(13):1769-1781.
Inhibition of AKT suppresses the initiation and progression of BRCA1-associated mammary tumors.
AZD2281 (Olaparib) purchased from AbMole
|Source||Int J Biol Sci (2018 Oct). Figure 5. Olaparib (Abmole Bioscience, Houston, USA)|
|Results||The overall RTVs (treated vs. non-treated tumors) for mice bearing Brca1-mutant tumor allografts were 60.8% and 62.6% for mice treated with MK-2206 and olaparib, respectively.|
|Source||Int J Biol Sci (2018 Oct). Figure 4. Olaparib (Abmole Bioscience, Houston, USA)|
|Results||In mice co-treated with olaparib and MK-2206, tumor volume was only increased ~1.8-fold at this same time, indicating that these agents exerted a additive effect on tumor growth.|
|Source||Int J Oncol (2015). Figure 4. AZD2281|
|Cell Lines||HCC‑1428 cells|
|Incubation Time||4 day|
|Results||Inhibition of autophagy by knocking down ATG5 also partially inhibited AZD2281-induced apoptosis, suggesting that autophagy contributes to AZD2281-induced cell death in BRCA mutated breast cancer cells.|
|Source||Int J Oncol (2015). Figure 1. AZD2281|
|Method||Transmission electron microscopy|
|Cell Lines||BRCA1 or BRCA2 mutant breast cancer cell lines|
|Incubation Time||4 day|
|Results||The growth inhibition effect of AZD2281 was significantly higher in the BRCA wild-type cell lines with BRCA1 allelic loss than in the BRCA wild-type cell line without BRCA1 allelic loss.|
|Cell lines||SW620 colorectal cell line|
|Preparation method||Potentiation of MMS Cytotoxicity by 47 Determined by the Use of Sulforhodamine B Cell Growth Assays. SW620 cells were seeded in 96-well plates and were left to attach overnight. Cells were preincubated with vehicle control (DMSO) or with a single concentration of KU-0059436 (1, 3, 10, 30, 100 or 300 nM) for 1 h before the addition of increasing concentrations of MMS. Cells were incubated in the presence of each drug combination for 4 days before cell growth was quantified by the use of an SRB assay.44 Data were calculated from triplicate wells as the mean percentage of cell growth relative to KU-0059436-only wells, and (SE and IC50 were calculated by the use of XL-FIT 4 software. SW620 cells showed <24% growth inhibition (>76% cell growth) when only KU-0059436 was used at concentrations below 300 nM (data not shown).|
|Concentrations||1, 3, 10, 100 and 300 nM|
|Incubation time||4 days|
|Animal models||mouse bearing SW620 xenografted tumors|
|Dosages||10 mg/kg once daily for 5 consecutive days|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells.
Bajrami et al. EMBO Mol Med. 2012 Aug 30. PMID: 22933245.
Clinical trials and future potential of targeted therapy for ovarian cancer.
Itamochi et al. Int J Clin Oncol. 2012 Aug 28. PMID: 22926640.
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA proficient triple negative breast cancer to PARP inhibition.
Ibrahim et al. Cancer Discov. 2012 Aug 24. PMID: 22915752.
Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.
Daemen et al. Breast Cancer Res Treat. 2012 Sep;135(2):505-17. PMID: 22875744.
Olaparib , PARP1 inhibitor in ovarian cancer.
Marchetti et al. Expert Opin Investig Drugs. 2012 Jul 13. PMID: 22788971.
|Related PARP Products|
Benzamide is an inhibitor of poly(ADP-ribose) polymerase with an IC50 of 3.3 μM.
Picolinamide is a strong inhibitor of poly (ADP-ribose) synthetase of nuclei from rat pancreatic islet cells.
|Niraparib (MK-4827) tosylate
Niraparib (MK-4827) tosylate is an excellent PARP1 and PARP2 inhibitor with IC50 of 3.8 and 2.1 nM, respectively.
Daidzein is an inactive analogue of genistein, a tyrosine kinase inhibitor and an estrogen receptor activator.
NMS-P118 is a potent, orally available, and highly selective PARP-1 inhibitor endowed with excellent ADME and pharmacokinetic profiles, showing 150-fold selectivity for PARP-1 over PARP-2 (Kd 0.009 μM vs 1.39 μM, respectively).
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.